pharma.markets

pharma.markets

  • HOME
  • Imprint

vaccine

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

24/12/2022 MaP 0

BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) today announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company’s […]

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

21/12/2022 MaP 0

BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with […]

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

06/12/2022 MaP 0

PDF Version Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have submitted an application to the U.S. Food and […]

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

22/08/2022 MaP 0

Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age […]

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®

08/07/2022 MaP 0

… For Adolescents 12 through 15 Years of Age COMIRNATY® is the first and only COVID-19 vaccine to be granted FDA approval for adolescents 12 […]

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

17/06/2022 MaP 0

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]

BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa

16/02/2022 MaP 0

Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the […]

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA

01/02/2022 MaP 0

With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy […]

Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant

24/01/2022 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of […]

Spanish vaccine shows good results against omicron variant

05/01/2022 MaP 0

The future Spanish vaccine against covid, on which the Hipra laboratories based in Amer (Girona) are working, is showing good results against the omicron variant, […]

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

23/12/2021 MaP 0

– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants – Third dose produced increased immune responses comparable to […]

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

10/12/2021 MaP 0

PDF Version First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older Pfizer Inc. (NYSE: PFE) […]

News on Spanish vaccine PHH-1V from HIPRA and the new B.1.1.159 variant

27/11/2021 MaP 0

Spanish company Hipra says it could adapt its vaccine PHH-1V to a new variant B.1.1.529 within four months The Spanish company expects to receive approval […]

AEMPS authorizes Phase IIb clinical trial of HIPRA Covid-19 vaccine

16/11/2021 MaP 0

The main objectives are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to […]

Copyright European Commission 2021

The Spanish vaccine against covid, close to commercialisation

30/10/2021 MaP 0

The Government approves funding to Hipra laboratories for its serum to advance to the final stages of clinical trials before its commercialisation. EFE The Centre […]

Posts navigation

1 2 … 4 »

Translation

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • Cosmetics
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • Bayer expands global clinical program for darolutamide in prostate cancer
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

Archive

  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Bayer expands global clinical program for darolutamide in prostate cancer

    23/03/2023 0
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    21/03/2023 0
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

    20/03/2023 0
  • Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer

    20/03/2023 0
  • New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

    20/03/2023 0
Archives
  • March 2023 (15)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid bayer biontech cancer commission companies coronavirus covid-19 covid19 economy elpais.com emergency eu europe european fda food global guarantee health hygiene investment links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support test vaccine who

Copyright © 2023 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner